ClinicalTrials.gg
CompletedNCT03588130Updated Nov 14, 2022

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

A Phase 2 interventional study of EscharEx (5% EX-02 formulation) and Gel Vehicle in Venous Leg Ulcer, sponsored by MediWound Ltd. Completed at 22 sites in 2 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by MediWound Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies in Varicose Ulcer with a site in United States — 33 open to participants now, 43 under way, 4 of them phase 3. Varicose Ulcer · United States.

Enrollment
45th of 132
120 · median 53
Started
2019
with 7 others
Phase 2
17 of 155
1 open now
Registered
88th of 155
by date
Lead sponsor
3 of 155
MediWound Ltd

Among the 155 studies in Varicose Ulcer with a site in United States, this one is the 45th largest by enrollment of the 132 interventional ones that give a count, is one of 8 that started in 2019, is one of 17 in phase 2, and was the 88th registered.

Varicose Ulcer

370 studies on the registry are indexed under Varicose Ulcer; 74 are open to participants now.

Browse Varicose Ulcer studies →

Open to participants now

33 of the 155 studies in Varicose Ulcer with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Varicose Ulcer with a site in United States, or all of them as a file.
02

Study summary

This study is a multicenter, prospective, randomized, placebo controlled, adaptive design study performed to assess the safety and the efficacy of 5% EscharEx (EX-02) compared to Gel Vehicle (placebo) and non-surgical standard of care (NSSOC), in debridement of Venous Leg Ulcers (VLU) (in a ratio of 2:2:1) in debridement of VLU.

The main objective of this study is:

To assess the safety and the efficacy of EscharEx (EX-02 formulation) compared to Gel Vehicle (placebo) and non-surgical standard of care (NSSOC), in debridement of Venous Leg Ulcers (VLU).

120 randomized adult patients with VLU that fail to heal for 4 weeks to 2 years, and with >50% non-viable tissue (necrotic/slough/fibrin) on the VLU. The maximum number of patients to be enrolled is 160.

The total duration of the study of each participating subject is up to 17 weeks: screening (1 week) + Daily visit period (up to 2 weeks) + Twice-weekly visits period (2 weeks) + Weekly visits period (10 weeks) + closure confirmation (up to 2 weeks, if applicable).

Each patient will go through 4 periods during the trial:

  1. Screening period (2 visits, 7 [+2] days apart). Including: recording demographics, medical history and concomitant medications, vital signs, physical examination, clinical laboratory tests, wound photography and assessments and questionnaires (pain, wound status and QoL). During this period, wounds will be treated by standard treatment (e.g. appropriate dressing, compression bandage) per investigator discretion, with the exclusion of mechanical and surgical debridement.

    During the one week screening period, patients whose wound size (surface area, as measured by eKare inSightTM) decreases by more than 20 percent will be excluded.

  2. Daily visits period (up to 8 daily site visits within up to 14 days): During the Daily visit period, the patient will arrive daily to site visits. During each visit, adverse events, concomitant medication, vital signs and pain will be recorded, the wound will be washed, photographed and assessed for wound size (by eKare inSightTM), % of non viable tissue (by clinical assessment), and wound healing status (assessed clinically).

    Eligible patients will be randomized into one of the study arms: EX-02, or Gel Vehicle (Placebo), or NSSOC in a 2:2:1 ratio. Patients will be treated with up to 8 daily 24±3 hours applications or until complete debridement is achieved, whichever occurs first.

    On the weekends between treatments of EX-02 or Gel material, the wound will be dressed with a compatible dressing, and by compression therapy. Patients treated with NSSOC continue using NSSOC during the weekend according to label or instructions for use, and compression therapy.

  3. Twice-weekly visits period (4 visits within 14 days): the patients will be followed twice weekly for two weeks, (4 visits within 14 days). During each visit, safety parameters will be recorded (AEs, concomitant medications, pain, vital signs), the wound will be washed, photographed and assessed for wound size (by eKare inSightTM), % of nonviable tissue (by clinical assessment), and wound healing status (assessed clinically).

    The investigator will clinically assess complete debridement, upon achieving a viable wound bed after removal of all non-viable tissue, suitable for initiation of the wound healing stage.

  4. Weekly visits period (up to10 visits within up to 10 weeks): patients will be followed once weekly for 10 weeks or until complete wound closure was achieved, (up to10 visits within up to 10 weeks). During each weekly visit, safety parameters will be recorded (AEs, concomitant medications, pain, vital signs), the wound will be washed, photographed and assessed for wound size (by eKare inSightTM), % of nonviable tissue (by clinical assessment), and wound healing status (assessed clinically).

The investigator will clinically assess complete debridement, upon achieving a viable wound bed after removal of all non-viable tissue, suitable for initiation of the wound healing stage.

Complete wound closure defined as skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visits, 2 weeks apart will be assessed clinically. Thus, if closure occurs close to the end of weekly visit period, i.e. on 9th or 10th visit of the weekly period, an additional confirmation visit will be performed 2 weeks later.

03

Conditions studied

  • Venous Leg Ulcer

Browse trials for

Keywords

  • Debridement
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients, men or women, between 18 and 90 years of age,
  2. Patients with a VLU (determined by medical history, physical examination, and an ultrasound scan demonstrating venous insufficiency),
  3. Wound is present for at least 4 weeks but no longer than 2 years.
  4. The necrotic/slough/fibrin non-viable tissue area is at least 50% of wound area (assessed by clinical evaluation),
  5. Target wound surface area is in the range of 2-100 cm2 (assessed by eKare inSightTM),
  6. Patient understands the nature of the procedure, is able to adhere to the protocol regimen, and provides a written prior to any study procedure.

Exclusion criteria

Exclusion Criteria

  1. Wound size decreased by > 20% after 1 week of standard-of-care-only period (screening period),
  2. Patients with more than one leg ulcer, on the leg of the target wound, with an area greater than or equal to 2cm2,
  3. Signs of infection including purulent discharge, deep-tissue abscess, erysipelas, cellulitis, etc.,
  4. Severely damaged skin (e.g. abrasion, exfoliation) extending >2 cm around the wound's edge,
  5. Presence of gangrene, signs of systemic infection, sepsis, or osteomyelitis during screening phase,
  6. Clinical suspicion of skin cancer (e.g. BCC, SCC, melanoma, sarcoma), which was not ruled out by ,
  7. Patients with skin disorders unrelated to the wound that are presented adjacent to the wound,
  8. Patients suffering from chronic skin disorders (Idiopathic Pruritus, Psoriasis, Panniculitis, Pyoderma Gangrenosum, etc.) that might deteriorate as a result of local trauma or debridement,
  9. Wound has sinus tracts or tunnels extending under healthy tissue (following debridement "un-roofing"- if relevant), or penetrating into joint capsule,
  10. Vascular operations in proximity to the wound in the last month,
  11. Patients with primary lymphatic edema,
  12. A significant decrease in the arterial blood flow of the extremity
  13. Patients with pre-enrolment wounds which are covered by eschar heavily saturated with iodine or by silver sulfadiazine (SSD) pseudoeschar (i.e. pseudoeschar as a result of SSD treatment),
  14. History of allergy or atopic disease or a known sensitivity to pineapples, papaya, bromelain or papain, as well as known sensitivity to latex proteins (known as latex-fruit syndrome), bee venom or olive tree pollen,
  15. Patients with poor nutritional status: albumin \< 2.5g/dl, poorly controlled Diabetes Mellitus (for diabetic patients; > 12%), anemia (\<8 g/dL), a leukocyte counts \< 3,800// μl or >15000/μl, \<100,000/μl, abnormal liver function (, ALT>2 x ), renal failure (Cr > 2.5 mg/dl), >48,
  16. Patients undergoing renal or peritoneal dialysis,
  17. Any condition that would preclude safe participation in the study, e.g. evidence of significant or unstable cardiovascular, pulmonary, liver, hematological, immunological, or neoplastic disease, or any immediate life threatening condition,
  18. Recent history (less than 6 months) of myocardial infarction (MI) or concurrent acute injury or disease that might compromise the patient's welfare,
  19. Patient is currently receiving, or has received at any time within three months prior to enrollment, any medications or treatments known to affect the wound healing processes; these include, chronic systemic intake with topical skin changes (i.e. thin, fragile skin with multiple heamatomas or previous laceration history) immuno-suppressive drugs, radiation therapy, immunomodulating medications and chemotherapy,
  20. Mentally incapacitated adults who are incapable of giving legal consent (e.g. dementia, psychiatric patients, etc.),
  21. Concurrent use of non-approved drugs or alcohol abuse,
  22. Pregnant women (positive pregnancy test) or nursing mothers,
  23. Exposure to intervention within three months prior to enrollment, or anticipated participation in another investigational drug trial or other intervention trial, while enrolled in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    EscharEx (5% EX-02 formulation)

    Debridement will be performed with 5% EX-02 for 24±3 hours, up to 8 applications

    Drug: EscharEx (5% EX-02 formulation)

  • Placebo comparator
    Gel Vehicle

    Debridement will be performed with Gel vehicle for 24±3 hours, up to 8 applications

    Drug: Gel Vehicle

  • Active comparator
    Non-surgical standard of care (NSSOC)

    Debridement will be performed with NSSOC (Santyl or commercially approved Hydrogel) per routine procedures, until complete debridement is achieved

    Drug: Non-surgical standard of care (NSSOC)

Interventions

  • Active arm

  • DrugGel Vehicle

    Control arm

  • DrugNon-surgical standard of care (NSSOC)

    Santyl (Enzymatic debridement) or commercially approved Hydrogel

06

What researchers measure

Primary outcomes

  1. Incidence of complete debridement in EX-02 vs. Gel Vehicle arms, scored dichotomously (yes/no), clinically assessed

    The clinical assessor will define complete debridement, after each application during the daily visits period

    Time frame: up to 8 applications, within 14 days

07

Study locations

22 sites
  • ILD Research Center
    Carlsbad, California 92009, United States
  • Limb Preservation Platform, Inc.
    Fresno, California 93710, United States
  • Felix Sigal. D.P.M, PC
    Los Angeles, California 90057, United States
  • Stanford
    Redwood City, California 94063, United States
  • Center for Clinical Research Inc.
    San Francisco, California 94115, United States
  • Medstar Health Georgetown University
    Washington, District of Columbia 20007, United States
  • C & R Research Services USA, Inc
    Coral Gables, Florida 33134, United States
  • INTEGRAL - Clinical Trials Solutions
    Doral, Florida 33126, United States
  • Barry University Clinical Research
    Miami Beach, Florida 33169, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114-2621, United States
  • Boston Medical Center/Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • South Shore Health System, Center for Wound Healing
    Weymouth, Massachusetts 02189, United States
  • Advanced Foot & Ankle Center
    Las Vegas, Nevada 89119, United States
  • Atlantic Health System - Overlook Wound Care Center
    Summit, New Jersey 07901, United States
  • Bey Lea Ambulatory Surgical Center
    Toms River, New Jersey 08753, United States
  • NYU Winthrop Hospital
    Mineola, New York 11501, United States
  • Mount Sinai St. Luke's Hospital
    New York, New York 10025, United States
  • Stony Brook University Hospital
    Stony Brook, New York 11794, United States
  • AZH Wound Center
    Milwaukee, Wisconsin 53221, United States
  • Hopitaux Universitaires de Geneva
    Geneva, Canton 1211, Switzerland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Dec 2021, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2018
First posted
Jul 17, 2018
StartActual
Dec 2, 2019
Primary completionActual
Dec 7, 2021
CompletionActual
Mar 23, 2022
Last update
Nov 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03588130
Lead sponsor
MediWound Ltd
Responsible party
Sponsor
First posted
Jul 17, 2018
Start date
Dec 2, 2019
Primary completion
Dec 7, 2021
Completion
Mar 23, 2022
Last update
Nov 14, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem bromelain

Start the discussion